Navigation Links
Antibiotic therapy improves moderate exacerbations of mild-to-moderate COPD
Date:9/7/2012

Antibiotic treatment with amoxicillin/clavulanate improves moderate exacerbations in patients with mild-to-moderate chronic obstructive pulmonary disease (COPD) and significantly prolongs the time between exacerbations, according to a new study from researchers in Spain.

"The existing evidence for antibiotic therapy in non-severe exacerbations of COPD is weak," said lead author Carl Llor, MD, PhD of the University Rovira i Virgili in Tarragona, Spain. "The results of our multicenter, randomized, double-blind, placebo-controlled trial show that antibiotic treatment is more effective than placebo in these patients, with an absolute difference in cure rates of 14.2%, and that the median time to next exacerbation is prolonged with antibiotic treatment, compared with placebo, from 160 to 233 days."

The findings were published online ahead of print publication in the American Thoracic Society's American Journal of Respiratory and Critical Care Medicine.

A total of 310 patients were enrolled in the study and randomized to receive either amoxicillin/clavulanate (500/125 mg) or placebo three times daily for eight days. All participants were at least 40 years old and had a spirometrically-confirmed diagnosis of mild-to-moderate COPD. The primary endpoint was clinical cure at the end of therapy visit.

A total of 117 patients in the amoxicillin/clavulanate group (74.1%) and 91 in the placebo group (59.9%) were considered cured at follow-up. Median time to next exacerbation was significantly longer in the amoxicillin/clavulanate group. Clinical success, defined as either cure or improvement, was achieved in 90.5% of the antibiotic-treated group, compare with 80.9% of the placebo group. Capillary C-reactive protein (CRP) at a cutoff of 40 mg/l was found to be an excellent predictor of clinical outcome; patients with CRP levels below 40 mg/l were significantly more likely to be cured without the use of antibiotics.

The study had a few limitations, including a limited sample size and the lack of objective assessment of symptom resolution at follow-up, other than peak flow measurements.

"The clinical success rate we saw with amoxicillin/clavulanate treatment in our patients with mild-to-moderate COPD is higher than what has been seen in previous placebo-controlled trials which included patients with severe COPD," Dr. Llor said. "This suggests an effect of the severity of airflow obstruction on the rate of treatment success."

"We have shown that antibiotic treatment is superior to placebo in improving exacerbations in mild-to-moderate COPD," Dr. Llor concluded. "Many of these patients are treated in primary care settings, and our study supports the use of antibiotics to treat mild to moderate airway obstruction, mainly in patients with elevated CRP levels."


'/>"/>
Contact: Nathaniel Dunford
ndunford@thoracic.org
212-315-8620
American Thoracic Society
Source:Eurekalert

Related medicine news :

1. Environmental Gene-Swapping May Play Part in Antibiotic Resistance
2. Antibiotic Use in Infants Tied to Overweight Later: Study
3. A nonantibiotic approach for treating urinary tract infections
4. Two Antibiotics Linked to Liver Injury in Elderly
5. Gonorrhea Resistant to All But One Antibiotic: CDC
6. Timing of antibiotics important in reducing infections after C-section
7. Researchers unveil molecular details of how bacteria propagate antibiotic resistance
8. VCU medical team recommends preventive antibiotic for COPD sufferers
9. Study examines role of seasonal prescribing changes in antibiotic resistance
10. Trivedi Beef, LLC Announces Breakthrough Beef Industry Data without the use of Antibiotic Drugs, Hormones or Steroids
11. A non-antibiotic approach for treating urinary tract infections
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/25/2017)... ... , ... Your World Insurance Services, a long-time Redlands insurance and financial services ... of owner Stacy Boyle to give back to the many charitable organizations that help ... high school,” said Ms. Boyle. “My father passed away without life insurance, and my ...
(Date:9/25/2017)... (PRWEB) , ... September 25, 2017 , ... ... to Arizona State University student Ashlea Grabau. The $1000 student scholarship is awarded ... 2017 scholarship was awarded to Ashlea Grabau who is a medical student at ...
(Date:9/25/2017)... ... 25, 2017 , ... Sensogram Technologies Inc. today launched an ... watch. VitalBand provides elite level fall detection, automatically calls any number you ... quickly. Plus, it’s a fully functioning smart watch and activity tracker. , ...
(Date:9/25/2017)... ... September 25, 2017 , ... The Coleman Institute, a ... an affiliate in Minneapolis-St. Paul, MN, Dr. Adam Locketz. Dr. Locketz will be ... aftercare planning through his Timewise Medical practice in the twin cities. , ...
(Date:9/25/2017)... ... ... The Renal Support Network (RSN) is proud to announce the launch of ... focused on RSN’s mission to empower people who have kidney disease to become knowledgeable ... Our unique website is loaded with hundreds of exclusive personal stories. These posts are ...
Breaking Medicine News(10 mins):
(Date:9/5/2017)... Sept. 5, 2017 Sapheneia and Scannerside received ... Scannerside DoseCheck is a third-party Vendor neutral CT product ... and allows compliance with current MITA standards. ... 29 DoseCheck solution is specifically designed to provide CT ... potential radiation doses over a predefined threshold. Scannerside Dose ...
(Date:9/5/2017)... , Sept. 5, 2017 Oramed Pharmaceuticals Inc. ... ), a clinical-stage pharmaceutical company focused on the development ... has successfully concluded its meeting with the U.S. Food ... oral insulin formulation. ... the regulatory pathway for submission of ORMD-0801, would be ...
(Date:8/31/2017)... Aug. 31, 2017 PM360,s annual Innovations ... to the latest innovations happening across the industry. Established ... to focus on providing a comprehensive look at the ... covers the most innovative companies, startups, divisions, products, services, ... "Everyone in this industry wants to ...
Breaking Medicine Technology: